Source:
https://scmp.com/business/companies/article/2131230/why-most-small-players-may-not-survive-chinas-pharmaceuticalCompanies
Why most small players may not survive China’s pharmaceutical industry consolidation
Strategy aims to turn China’s predominantly off-patent drug copying pharmaceutical industry into one that’s capable of coming up with innovative patentable products
China’s fragmented pharmaceutical industry is expected to undergo a wave of consolidation over the next five years, thanks to more stringent drug quality regulations and a reduction in layers of distribution intermediaries, according to Credit Suisse. Photo: Shutterstock
China’s fragmented pharmaceutical industry is expected to undergo a wave of consolidation over the next five years, thanks to more stringent drug quality regulations and a reduction in layers of distribution intermediaries.
From upstream drug discovery and manufacturing to downstream distribution, companies face greater competitive pressure as Beijing implements a raft of measures announced over the past two years to weed out practices that had led to mediocre drug quality and inefficiencies.